IndraLab

Statements


USP13 activates BCL2. 1 / 1
| 1

reach
"We further report that genetic or pharmacological inhibition of USP13 considerably reduces MCL1 protein abundance and significantly increases tumor cell sensitivity to BH3 mimetic inhibitors targeting BCL-2 and BCL-XL."